MENU

Published on 13/03/2018 2:51:57 PM | Source: Dion Global Solutions Ltd

Lupin bags approval for Tydemy Tablets

Posted in Stock Market| #Lupin Ltd #Stock Market #Pharma Sector

Pharma major Lupin has said that it has launched its Tydemy Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg and Levomefolate Calcium, 0.451mg) having received an approval from the United States Food and Drug Administration (FDA). Lupin's Tydemy (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg) are the generic equivalents of Bayer HealthCare Pharmaceuticals Inc.'s Safyral® tablets.

It is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception. Drospirenone, EE, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg tablets had annual sales of approximately USD 22 million in the US (IQVIA January 2018). Meanwhile, shares of the company were trading at Rs 778.55 apiece, up 1.10 per cent from the previous close at 14:03 hrs on BSE.